The latest focus on new liver cirrhosis therapies has put Mirum Pharmaceuticals (MIRM) in the spotlight, as its Volixibat candidate features among emerging drugs being tracked across this developing treatment market
Despite the spotlight on Volixibat, Mirum Pharmaceuticals’ share price has softened recently, with a 30 day share price return of down 14.43% and a 7 day share price return of down 3.12%. However, the 1 year total shareholder return of 34.69% and very large 5 year total shareholder return show longer term holders have seen strong gains overall
If this kind of biotech story has your attention, it can be useful to look across the sector and see what else is emerging through the 40 healthcare AI stocks
Bulls argue Mirum Pharmaceuticals’ pullback sits at odds with its rare disease portfolio and revenue growth, while bears point to ongoing losses and clinical risk. Which side does the current valuation appear to favor next?
Advertisement
Most Popular Narrative: 32.9% Undervalued
Mirum Pharmaceuticals last closed at $96.72 compared with a narrative fair value estimate of $144.15, which frames the current pullback against a higher implied worth
The expanding addressable patient population for Mirum’s therapies, especially with the increased recognition and diagnosis of later-onset PFIC through broader use of genetic testing and heightened disease awareness, is driving higher-than-expected patient volumes. This growing patient base is expected to directly contribute to sustained top-line revenue growth
Want to see what is behind that growth story for Mirum Pharmaceuticals? The narrative focuses on rising rare disease revenue, improving margins, and an earnings profile that depends on ambitious long term forecasts. Curious which assumptions really carry that $144.15 fair value?
Result: Fair Value of $144.15 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts
However, Mirum Pharmaceuticals still carries meaningful risk if Livmarli underperforms expectations or if pressures on rare disease drug pricing reduce the earnings power that analysts are building into their models
Find out about the key risks to this Mirum Pharmaceuticals narrative
Next Steps
The split sentiment around Mirum Pharmaceuticals, with both risks and rewards in play, makes this a moment to move quickly and test the story against hard data for yourself. To weigh the upside against the concerns in a structured way, start with the 3 key rewards and 2 important warning signs
Looking for more investment ideas beyond Mirum Pharmaceuticals?
If you like the rare disease story around Mirum Pharmaceuticals, do not stop your research here. Use the Simply Wall St Screener to compare other opportunities and pressure test your portfolio decisions
- Pinpoint potential bargains by scanning companies that combine quality fundamentals with attractive valuations using the 49 high quality undervalued stocks.
- Build a steadier income stream by reviewing companies known for stronger yield profiles through the 12 dividend fortresses.
- Dial down portfolio risk by focusing on businesses that show stronger resilience scores with the 74 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free
• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks
Try a Demo Portfolio for Free
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
MI
mitchell_lawler
The Foxhole
Druckenmiller says cheap money’s days are numbered. Boring, self-funding companies could be the opportunity
810
DE
devon_jd1501h
Leverage on its own is close to useless as a screen right now, because so much corporate debt was termed out at 2 to 3% and has not repriced. A business at three times leverage with nothing due until 2031 is in a completely different position from the same ratio rolling next year. Screen on weighted average maturity and the schedule behind it
LE
LeverageIsLovely2h
In my view, Insurance companies are best positioned for this
Mitchell Lawler
Market Insights
Which payment stocks actually get paid?
Every new payment app was supposed to kill Visa and Mastercard. Instead, they got bigger. So what does that mean for the payment stocks on your radar?
32
Aug 20, 2026
About NasdaqGM:MIRM
Mirum Pharmaceuticals
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases
See The Free Research Report
Undervalued with high growth potential
See The Free Research Report
Market Insights
Which payment stocks actually get paid?MI
Mitchell Lawler
Picking portfolio winners takes more than hot airAN
Andrew Legget
What Korea’s market says about your index fundMI
Mitchell Lawler
Advertisement
Weekly Picks
RI
Rick_Orfordon Starfighters Space·18 days ago
The 1960s Fighter Jet That Could Crack Open a $20 Billion Satellite Market
Fair Value:US$524.2% undervalued
64followersusers have followed this narrative
·4commentsusers have commented on this narrative
·11likesusers have liked this narrative
TR
tripledubon Meta Platforms·21 days ago
The $135 Billion Bet That Should Make Every Shareholder Nervous
Fair Value:US$5864.6% undervalued
45followersusers have followed this narrative
·3commentsusers have commented on this narrative
·33likesusers have liked this narrative
TA
Taloson Voyager Technologies·16 days ago
The “Landlord of Orbit” – A Deep Value Play Ahead of the Starlab Era
Fair Value:US$385.290.8% undervalued
31followersusers have followed this narrative
·0commentsusers have commented on this narrative
·5likesusers have liked this narrative
IV
Ivoedon Uber Technologies·10 days ago
Uber’s Valuation Depends On Who Captures The Economics Of Driverless Rides
Fair Value:US$11631.6% undervalued
7followersusers have followed this narrative
·0commentsusers have commented on this narrative
·3likesusers have liked this narrative
RecentlyUpdated Narratives
EP
Epstein_Researchon Silver Storm Mining·26 minutes ago
Silver Storm Mining, oversold silver junior
Fair Value:CA$273.0% undervalued
5followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
RI
RisbergCapitalon Coloplast·about 4 hours ago
Coloplast: A Rare Entry Point in Quality Healthcare
Fair Value:DKK 73737.2% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
RI
RisbergCapitalon Hemnet Group·about 4 hours ago
Hemnet: Priced As If the Freeze Were Permanent
Fair Value:SEK 17845.9% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
OS
oscargarciaon NVIDIA·3 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century
Fair Value:US$28025.5% undervalued
348followersusers have followed this narrative
·9commentsusers have commented on this narrative
·16likesusers have liked this narrative
CU
CubanEroson Microsoft·about 2 months ago
A wonderful business at reasonable price
Fair Value:US$419.9116.1% overvalued
197followersusers have followed this narrative
·0commentsusers have commented on this narrative
·9likesusers have liked this narrative
KI
KiwiInveston Amazon.com·4 months ago
Amazon’s high growth, high tech segments propel its profits, while traditional segments plod along
Fair Value:US$475.0944.8% undervalued
223followersusers have followed this narrative
·1commentusers have commented on this narrative
·8likesusers have liked this narrative
